Monte Rosa Therapeutics (GLUE) Revenue & Revenue Breakdown
Monte Rosa Therapeutics Revenue Highlights
Latest Revenue (Q)
$4.70M
Monte Rosa Therapeutics Revenue by Period
Monte Rosa Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Monte Rosa Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $4.70M | 341.26% |
2024-03-31 | $1.06M | -87.84% |
2023-12-31 | $8.75M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | - |
Monte Rosa Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
KYMR | Kymera Therapeutics | $78.59M | $10.29M |
NRIX | Nurix Therapeutics | $76.99M | $12.09M |
FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
IKNA | Ikena Oncology | $9.16M | - |
STOK | Stoke Therapeutics | $8.78M | $4.22M |
GBIO | Generation Bio | $5.90M | $4.06M |
STTK | Shattuck Labs | $1.66M | $1.61M |
LYEL | Lyell Immunopharma | $130.00K | $3.00K |
DSGN | Design Therapeutics | - | - |
GRCL | Gracell Bio | - | - |
NKTX | Nkarta | - | - |
ERAS | Erasca | - | - |
SANA | Sana Bio | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
GLUE Revenue FAQ
What is Monte Rosa Therapeutics’s yearly revenue?
Monte Rosa Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. GLUE's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Monte Rosa Therapeutics’s quarterly revenue?
Monte Rosa Therapeutics's quarterly revenue for Q2 2024 was $4.7M, a 341.26% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.06M, a -87.84% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). GLUE's quarterly revenue for Q4 2023 was $8.75M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Monte Rosa Therapeutics’s revenue growth rate?
Monte Rosa Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.